Chicago-based Meitheal Pharmaceuticals, along with its Chinese parent, was busy in 2024, adding both biosimilar drugs and ...

Ivacaftor Oral Granules, 25 mg, 50 mg and 75 mg per unit dose packet are indicated for cystic fibrosis treatment in patients ...

Drugmakers have started 2025, implementing price hikes for 583 products within the first two days of the new year alone, ...

Despite concerns over cabozantinib's patent expiry, Exelixis projects robust future revenues, with lead pipeline candidate ...

Influenza is affecting hundreds of thousands of people in Japan and rising rapidly among that nation's population of 124.5 ...

The FDA has approved Liraglutide Injection, the first generic version of Victoza, for the treatment of type 2 diabetes.

A collaboration between a drug plan and clinical pharmacists led to nearly 50% of members successfully switching to a preferred dipeptidyl-peptidase-4 inhibitor.

New research from University of Iowa dispels the belief that pharmaceutical mergers lead to higher drug prices, showing a decrease in prices for generic drugs.

Catalyst Pharmaceuticals settles patent litigation with Teva, delaying generic Firdapse launch until 2035. Legal actions against other defendants remain ongoing.

The US FDA approved the first generic referencing Victoza, a GLP-1 receptor agonist indicated to improve glycemic control.

Despite weathering significant criticism from lawmakers and patient groups over the steep cost of its rare disease med ...

In the ‘80s, researchers set out to test a medication called sildenafil citrate for treating high blood pressure and angina ...